Plus Therapeutics Profit Margin

Plus Therapeutics posts a profit margin of 535.25% as of June 2026. That compares with -776.93% in the prior-year period — up 168.9% year over year. That is above the Healthcare sector average of 13.76%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Plus Therapeutics's profit margin was -776.93%. The latest reading is 535.25% — a 168.9% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.76% is typical. Plus Therapeutics's 535.25% is higher that level. That is roughly 3789.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Plus Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 535.25% as of June 2026; use YoY and peer views to separate noise from signal.

Context for PSTV's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.76%), and (3) consistency with growth and profitability. This page covers the first two; Plus Therapeutics's other metric pages and overview cover the third.